生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 12-23 16:00:00

5,800.752

-99.668

-1.69%

最高5,936.155	最低5,782.674	成交量1.18亿
今开5,900.303	昨收5,900.420	日振幅2.60%
总市值0.00	流通市值0.00	总股本0.00
成交额36.53亿	换手率--	流通股本0.00
市净率7.589256	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5800.7515,"timestamp":1766477287247,"preClose":5900.42,"halted":0,"volume":117721244,"delay":0,"changeRate":-0.016892,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-99.668457,"latestTime":"12-23 16:00:00","open":5900.3027,"high":5936.155,"low":5782.6743,"amount":3653203876,"amplitude":0.026012,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"pbRate":7.589256,"peRate":-77.859758,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2593418484","title":"和誉-B(02256)：口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418484","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418484?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:02","pubTimestamp":1766534531,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，其口服、高活性、高选择性小分子KRAS G12D抑制剂ABSK141用于治疗携带KRAS G12D突变的晚期实体瘤患者的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","IND","LU2476274720.SGD","IE00BPRC5H50.USD","LU2488822045.USD","02256","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2778985437.USD","BK1161"],"gpt_icon":0},{"id":"2593418349","title":"科济药业-B(02171)12月23日斥资486.09万港元回购32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418349","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418349?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:16","pubTimestamp":1766495776,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布公告，于2025年12月23日该公司斥资486.09万港元回购32万股，回购价格为每股14.98-15.25港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1587","BK1161","BK1574","02171"],"gpt_icon":0},{"id":"2593541395","title":"年内险资举牌39次：偏爱红利资产，科技板块迎布局机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2593541395","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593541395?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:10","pubTimestamp":1766495400,"startTime":"0","endTime":"0","summary":"随着中邮保险的举牌成功，今年险资的举牌次数达到39次，仅次于2015年的62次，为历史第二高。从举牌资产所属板块来看，传统板块仍具有压舱石地位，但科技板块的比重有望增加。截至12月23日，2025年以来险资举牌共计39次，创2016年以来新高。例如，弘康人寿今年6月27日首次举牌郑州银行H股，并在此后进行了16次增持，最新持股比例达22.14%，累计触发4次举牌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122321153997a099a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122321153997a099a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1161","01658","03968","02696"],"gpt_icon":0},{"id":"2593419285","title":"普华永道徐佳：中国创新药迎分水岭，量质转型呈分化格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419285","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419285?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:54","pubTimestamp":1766494448,"startTime":"0","endTime":"0","summary":"普华永道中国医药医疗行业主管合伙人徐佳博士在接受21世纪经济报道记者专访时指出，中国创新药已进入“量质转型的分水岭阶段”，呈现“头部崛起、中小突围”的分化格局，而非行业全面复苏。当前，随着2025年国家医保药品目录正式披露，支付端对创新药的支持力度","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0455707207.USD","HK0000165453.HKD","LU1969619763.USD","BK1161","LU2097828474.EUR","01801","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","BK1583","BK1589","BK1574","LU2328871848.SGD","01530","06978","LU0502904849.HKD","LU2242644610.SGD"],"gpt_icon":0},{"id":"1190294673","title":"再鼎医药宣布Cobenfy（氟哌啶醇和氯化托烷）在中国获批，为首个治疗精神分裂症的创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1190294673","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190294673?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:30","pubTimestamp":1766493018,"startTime":"0","endTime":"0","summary":"再鼎医药宣布Cobenfy（氟哌啶醇和氯化托烷）在中国获批，为首个治疗精神分裂症的创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1588","BK1161","09688","BK1574"],"gpt_icon":0},{"id":"2593497421","title":"银诺医药-B荣获“格隆汇金格奖·年度卓越创新力IPO”奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2593497421","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593497421?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:27","pubTimestamp":1766492822,"startTime":"0","endTime":"0","summary":"格隆汇12月22日线上举办“科技赋能·资本破局”分享会。备受瞩目的卓越公司评选榜单隆重揭晓。其中，格隆汇“金格奖”年度卓越公司评选中，银诺医药-B(02591.HK)荣获“年度卓越创新力IPO”奖项。\r\n\r\n　　“年度卓越创新力IPO”奖项是对公司过去一年在产品创新、模式创新、组织创新等方面进行考量，旨在表彰以持续创新紧跟市场步伐，在模式与路径上获得优秀成果的新上市公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251223/31885620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2593497198","title":"天价“抗癌针”成本有望降至万元以内——专访科济药业董事会主席李宗海","url":"https://stock-news.laohu8.com/highlight/detail?id=2593497198","media":"中国基金报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593497198?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:23","pubTimestamp":1766492630,"startTime":"0","endTime":"0","summary":"【导读】科济药业董事会主席李宗海：通用型CAR-T产品有望将成本降至1万元/针左右作为革命性的癌症免疫治疗方法，CAR-T细胞疗法被认为是目前最有前景的肿瘤治疗方式之一，但其高达百万元的治疗费用却让众多普通患者望而却步。不过，此种状况有望迎来积极的变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599719764.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599719764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02171","BK1161","BK1587","BK1585","BK1574"],"gpt_icon":0},{"id":"2593492550","title":"瑞科生物-B(02179)：选举徐浩宇担任董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2593492550","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593492550?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:47","pubTimestamp":1766490448,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B 发布公告，公司董事会于2025年12月22 日收到刘勇博士的辞职报告。为了进一步提升公司治理水平及计划倾注更多时间于其他工作，刘勇博士辞去公司董事长及董事会提名委员会主席职务，自董事会选举产生新任董事长之日起生效。董事会欣然宣布，董事会于2025年12月23日召开的董事会会议上选举徐浩宇先生担任公司第二届董事会董事长，任期自董事会审议通过之日起至第二届董事会任期届满之日止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161"],"gpt_icon":0},{"id":"2593869497","title":"医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2593869497","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593869497?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:44","pubTimestamp":1766490240,"startTime":"0","endTime":"0","summary":"盐野义方面表示，预计该交易将于2026年4月1日或之后完成交割，交易完成后每年将为公司新增约7亿美元的全球销售额。根据官方披露，盐野义将以25亿美元的一次性付款方式收购Radicava相关业务，同时约定在“特定条件”下支付潜在的未来特许权使用费。交易交割后，Radicava业务单元将成为盐野义的全资子公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-12-23/doc-inhcuyui5237827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","BK1515","BK1574","BK1161","ADC","159938","BK4080","09939"],"gpt_icon":0},{"id":"1141035379","title":"维立志博与Dianthus Therapeutics宣布启动LBL-047（DNTH212）在健康志愿者和系统性红斑狼疮患者中的一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1141035379","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141035379?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:15","pubTimestamp":1766488533,"startTime":"0","endTime":"0","summary":"12月23日讯 - 南京维立志博（9887.HK）::*维立志博与Dianthus Therapeutics宣布启动LBL-047（DNTH212）在健康志愿者和系统性红斑狼疮（SLE）患者中的一期临床试验*南京维立志博有限公司：预计在2026年下半年公布健康志愿者的主要结果。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000500386.USD","BK1161","BK4139","HK0000252160.HKD","DNTH","HK0000252152.HKD"],"gpt_icon":0},{"id":"2593499067","title":"中慧生物-B(02627)：李建军获选为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2593499067","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593499067?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:31","pubTimestamp":1766485908,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B(02627)发布公告，有关委任李建军先生为公司独立非执行董事的建议决议案已于临时股东会上获正式通过。根据公司的章程，李先生已获选为董事会独立非执行董事。上述委任李先生后，董事会亦欣然宣布，自2025年12月23日临时股东会结束起，李先生已获委任为董事会审计委员会主席及董事会薪酬与考核委员会成员;于建林先生不再担任董事会提名委员会成员;李润香女士已获委任为董事会提名委员会成员;及陈乘贝先生已获委任为董事会提名委员会成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2593841941","title":"信达生物IBI356启动II期临床 适应症为中重度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2593841941","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593841941?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:03","pubTimestamp":1766484180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的一项评估IBI356在中重度特应性皮炎成人参与者中的有效性和安全性的多中心、随机、双盲、平行、安慰剂对照II期临床研究已启动。IBI356为生物制品，适应症为中重度特应性皮炎。特应性皮炎是一种慢性、复发性、炎症性皮肤病，主要症状有皮肤瘙痒、红斑、丘疹等。诊断主要依据典型临床表现及相关检查，如血清IgE检测等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223190257a6c5adcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223190257a6c5adcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2097828631.EUR","LU2097828805.USD","LU2097828714.EUR","LU0502904849.HKD","BK1583","BK1161","LU0455707207.USD","LU2488822045.USD","01801","BK1589","LU2097828474.EUR","LU2328871848.SGD","LU2097828557.USD","HK0000165453.HKD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2593446604","title":"百济神州BGB - 16673片启动II期临床 适应症为B细胞恶性肿瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446604","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593446604?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:03","pubTimestamp":1766484180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，百济神州（苏州）生物科技有限公司的一项评价Bruton酪氨酸激酶靶向蛋白降解剂BGB - 16673用于治疗B细胞恶性肿瘤患者的1/2期、开放性、剂量递增和扩展研究已启动。本次试验主要目的是评估BGB - 16673在B细胞恶性肿瘤患者中的安全性、耐受性、有效性、药代动力学和药效学，并确定扩展期推荐剂量和2期推荐剂量。BGB - 16673片为化学药物，适应症为B细胞恶性肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223190342a46ea8c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223190342a46ea8c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1500","LU1719994722.HKD","LU0307460666.USD","LU1969619763.USD","LU1251922891.USD","BK1583","LU2328871848.SGD","LU0588546209.SGD","LU1303224171.USD","BK1161","LU1770034418.SGD","BK1588"],"gpt_icon":0},{"id":"2593968554","title":"昊海生物科技(06826)12月23日斥资14.02万港元回购5500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593968554","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593968554?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:37","pubTimestamp":1766482631,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，该公司于2025年12月23日斥资14.02万港元回购5500股股份，每股回购价格为25.4-25.54港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251223/31885131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1593","06826"],"gpt_icon":0},{"id":"2593419490","title":"医药创新看中国：“一哥”恒瑞研发瞄定三大策略，构建全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419490","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419490?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:15","pubTimestamp":1766481352,"startTime":"0","endTime":"0","summary":"“中国在创新药研发管线方面的规模已占全球的四分之一左右，每年开展的临床试验数量约3000项，这两项关键指标均处于世界前列。”全球医药交易市场也在见证中国力量的崛起。而在创新队列中，恒瑞作为龙头企业，始终占据着重要位置。恒瑞医药董事长孙飘扬在2025年研发日上表示，恒瑞始终坚持创新与国际化战略。这些数据表明中国创新药正从“跟随式创新”迈向“全球领跑”的新阶段。一举创下国内史上BD单笔交易规模最大纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","BK1161","LU0359202008.SGD","BK1515","09939","LU0359201885.HKD","LU1023057109.AUD","01276","LU0359201612.USD","LU2543165471.USD"],"gpt_icon":0},{"id":"2593849898","title":"维立志博-B(09887)：LBL-024于铂耐药卵巢癌IB/II期试验的首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2593849898","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593849898?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:32","pubTimestamp":1766478731,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价奥帕替苏米单抗(PD-L1/4-1BB双特异性抗体LBL-024)用于治疗铂耐药卵巢癌的Ib/II期临床研究首例患者已成功用药。本次开展的开放标签、多中心Ib/II期临床研究由中国医学科学院肿瘤医院吴令英教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗联合紫杉醇治疗铂耐药卵巢癌患者的疗效及安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-024于铂耐药卵巢癌IB/II期试验的首例患者用药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"gpt_icon":0},{"id":"2593418537","title":"每日卖空追踪 | 诺诚健华 12月23日卖空量成交15万股，卖空比例为3.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418537?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478642,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月23日，跌0.08%，卖空量成交15万股，较上一交易日减少50.33%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163627a6c520a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163627a6c520a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09969"],"gpt_icon":0},{"id":"2593492881","title":"每日卖空追踪 | 映恩生物-B 12月23日卖空量成交1.46万股，卖空比例为3.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593492881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593492881?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478641,"startTime":"0","endTime":"0","summary":"映恩生物-B北京时间12月23日，跌0.67%，卖空量成交1.46万股，较上一交易日减少52.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163607a46e1a0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163607a46e1a0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252160.HKD","09606","HK0000252152.HKD","LU2543165471.USD","HK0000500386.USD"],"gpt_icon":0},{"id":"2593446611","title":"每日卖空追踪 | 科伦博泰生物-B 12月23日卖空量成交2.15万股，卖空比例为5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446611","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593446611?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478638,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间12月23日，涨1.31%，卖空量成交2.15万股，较上一交易日减少69.59%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163604a6c52043&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163604a6c52043&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2593446627","title":"每日卖空追踪 | 百济神州 12月23日卖空量成交10.33万股，卖空比例为5.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446627","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593446627?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478636,"startTime":"0","endTime":"0","summary":"百济神州北京时间12月23日，跌1.39%，卖空量成交10.33万股，较上一交易日减少52.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163542a46e197a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163542a46e197a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","BK1583","06160","LU0588546209.SGD","LU1719994722.HKD","BK1500","LU1969619763.USD","LU2328871848.SGD","LU0307460666.USD","LU1251922891.USD","LU1770034418.SGD","BK1161","BK1588"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.0281},{"period":"6month","weight":0.0596},{"period":"1year","weight":0.2963},{"period":"ytd","weight":0.2849}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}